Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to March 2014

Leukoaraiosis: A Hidden Cause Of Brain Aging

March 2014

By Clyde Eberley


  1. Available at: Accessed January 10, 2014.
  2. Sheline YI, Price JL, Vaishnavi SN, et al. Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors. Am J Psychiatry. 2008 Apr;165(4):524-32.
  3. Helenius J, Tatlisumak T. Treatment of leukoaraiosis: a futuristic view. Curr Drug Targets. 2007 Jul;8(7):839-45.
  4. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666.
  5. Schenk C, Wuerz T, Lerner AJ. Small vessel disease and memory loss: what the clinician needs to know to preserve patients’ brain health. Curr Cardiol Rep. 2013 Dec;15(12):427.
  6. Grueter BE, Schulz UG. Age-related cerebral white matter disease (leukoaraiosis): a review. Postgrad Med J. 2012 Feb;88(1036):79-87.
  7. Welker KM, De Jesus RO, Watson RE, Machulda MM, Jack CR. Altered functional MR imaging language activation in elderly individuals with cerebral leukoaraiosis. Radiology. 2012 Oct;265(1):222-32.
  8. Khan U, Porteous L, Hassan A, Markus HS. Risk factor profile of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):702-6.
  9. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997 Mar;28(3):652-9.
  10. Criqui MH, Browner D, Fronek A, et al. Peripheral arterial disease in large vessels is epidemiologically distinct from small vessel disease. An analysis of risk factors. Am J Epidemiol. 1989 Jun;129(6):1110-9.
  11. Choi JH, Bae HJ, Cha JK. Leukoaraiosis on magnetic resonance imaging is related to long-term poor functional outcome after thrombolysis in acute ischemic stroke. J Korean Neurosurg Soc. 2011 Aug;50(2):75-80.
  12. Schwartz GL, Bailey KR, Mosley T, et al. Association of ambulatory blood pressure with ischemic brain injury. Hypertension. 2007 Jun;49(6):1228-34.
  13. Thein SS, Hamidon BB, Teh HS, Raymond AA. Leukoaraiosis as a predictor for mortality and morbidity after an acute ischaemic stroke. Singapore Med J. 2007 May;48(5):396-9.
  14. Li H, Xu G, Xiong Y, et al. Relationship between Cerebral Atherosclerosis and Leukoaraiosis in Aged Patients: Results from DSA. J Neuroimaging. 2013 Sep 3.
  15. Gottesman RF, Coresh J, Catellier DJ, et al. Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2010 Jan;41(1):3-8.
  16. Uh J, Yezhuvath U, Cheng Y, Lu H. In vivo vascular hallmarksof diffuse leukoaraiosis. J Magn Reson Imaging. 2010 Jul;32(1):184-90.
  17. Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol. 2011 Feb;37(1):56-74.
  18. Webb AJ, Simoni M, Mazzucco S, Kuker W, Schulz U, Rothwell PM. Increased cerebral arterial pulsatility in patients with leukoaraiosis: arterial stiffness enhances transmission of aortic pulsatility. Stroke. 2012 Oct;43(10):2631-6.
  19. Calabro RS, Gervasi G, Baglieri A, Furnari A, Marino S, Bramanti P. Is high oral dose L-arginine intake effective in leukoaraiosis? Preliminary data, study protocol and expert’s opinion. Curr Aging Sci. 2013 Jul;6(2):170-7.
  20. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol. 2002 May;59(5):787-93.
  21. Deplanque D, Lavallee PC, Labreuche J, et al. Cerebral and extracerebral vasoreactivity in symptomatic lacunar stroke patients: a case-control study. Int J Stroke. 2013 Aug;8(6):413-21.
  22. Giwa MO, Williams J, Elderfield K, et al. Neuropathologic evidence of endothelial changes in cerebral small vessel disease. Neurology. 2012 Jan 17;78(3):167-74.
  23. Szolnoki Z. Genetic variant-associated endothelial dysfunction behind small-vessel cerebral circulatory disorders: a new pathomechanism behind common cerebral phenotypes. Mini Rev Med Chem. 2007 May;7(5):527-30.
  24. Khan U, Crossley C, Kalra L, et al. Homocysteine and its relationship to stroke subtypes in a UK black population: the south London ethnicity and stroke study. Stroke. 2008 Nov;39(11):2943-9.
  25. Hassan A, Hunt BJ, O’Sullivan M, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 2004 Jan;127(Pt 1):212-9.
  26. Censori B, Partziguian T, Manara O, Poloni M. Plasma homocysteine and severe white matter disease. Neurol Sci. 2007 Oct;28(5):259-63.
  27. Sachdev P, Parslow R, Salonikas C, et al. Homocysteine and the brain in midadult life: evidence for an increased risk of leukoaraiosis in men. Arch Neurol. 2004 Sep;61(9):1369-76.
  28. Naka H, Nomura E, Takahashi T, et al. Plasma total homocysteine levels are associated with advanced leukoaraiosis but not with asymptomatic microbleeds on T2*-weighted MRI in patients with stroke. Eur J Neurol. 2006 Mar;13(3):261-5.
  29. Harrington RA, Hodgson PK, Larsen RL. Cardiology patient page. Antiplatelet therapy. Circulation. 2003 Aug 19;108(7):e45-7.
  30. Kang SJ, Park BJ, Shim JY, Lee HR, Hong JM, Lee YJ. Mean platelet volume (MPV) is associated with leukoaraiosis in the apparently healthy elderly. Arch Gerontol Geriatr. 2012 Mar-Apr;54(2):e118-21.
  31. Culebras A. Cerebrovascular disease and sleep. Curr Neurol Neurosci Rep. 2004 Mar;4(2):164-9.
  32. Park JH, Ryoo S, Kim SJ, et al. Differential risk factors for lacunar stroke depending on the MRI (white and red) subtypes of microangiopathy. PLoS One. 2012;7(9):e44865.
  33. Putaala J, Kurkinen M, Tarvos V, Salonen O, Kaste M, Tatlisumak T. Silent brain infarcts and leukoaraiosis in young adults with first-ever ischemic stroke. Neurology. 2009 May 26;72(21):1823-9.
  34. Wright CB, Moon Y, Paik MC, et al. Inflammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke. 2009 Nov;40(11):3466-71.
  35. Zeevi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc. 2010 Sep;58(9):1749-57.
  36. Bokura H, Yamaguchi S, Iijima K, Nagai A, Oguro H. Metabolic syndrome is associated with silent ischemic brain lesions. Stroke. 2008 May;39(5):1607-9.
  37. Park K, Yasuda N, Toyonaga S, et al. Significant association between leukoaraiosis and metabolic syndrome in healthy subjects. Neurology. 2007 Sep 4;69(10):974-8.
  38. Seo SK, Jung I, Lee SM, et al. Relationship between leukoaraiosis and menopause in healthy middle-aged women. Fertil Steril. 2013 Aug;100(2):500-4.
  39. Szolnoki Z. Pathomechanism of leukoaraiosis: a molecular bridge between the genetic, biochemical, and clinical processes (a mitochondrial hypothesis). Neuromolecular Med. 2007;9(1):21-33.
  40. Pu Y, Liu L, Zou X, et al. Relationship between leukoaraiosis and cerebral large artery stenosis. Neurol Res. 2009 May;31(4):376-80.
  41. Poggesi A, Gouw A, van der Flier W, et al. Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. J Neurol. 2013 Apr;260(4):1014-21.
  42. Miki Y, Sakamoto S. Age-related white matter lesions (leukoaraiosis): an update. Brain Nerve. 2013 Jul;65(7):789-99.
  43. Macfarlane MD, Looi JC, Walterfang M, et al. Executive dysfunction correlates with caudate nucleus atrophy in patients with white matter changes on MRI: a subset of LADIS. Psychiatry Res. 2013 Oct 30;214(1):16-23.
  44. Schmidt R, Berghold A, Jokinen H, et al. White matter lesion progression in LADIS: frequency, clinical effects, and sample size calculations. Stroke. 2012 Oct;43(10):2643-7.
  45. Park K, Nakagawa Y, Kumagai Y, Nagahara M. Leukoaraiosis, a common brain magnetic resonance imaging finding, as a predictor of traffic crashes. PLoS One. 2013;8(2):e57255.
  46. Simoni M, Li L, Paul NL, et al. Age- and sex-specific rates of leukoaraiosis in TIA and stroke patients: population-based study. Neurology. 2012 Sep 18;79(12):1215-22.
  47. Briley DP, Haroon S, Sergent SM, Thomas S. Does leukoaraiosis predict morbidity and mortality? Neurology. 2000 Jan 11;54(1):90-4.
  48. Baezner H, Blahak C, Poggesi A, et al. Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology. 2008 Mar 18;70(12):935-42.
  49. Srikanth V, Beare R, Blizzard L, et al. Cerebral white matter lesions, gait, and the risk of incident falls: a prospective population-based study. Stroke. 2009 Jan;40(1):175-80.
  50. Berger K, Roesler A, Kretzschmar K. The association between white matter lesions, stroke and activities of daily living--the MEMO study on the KORA platform Augsburg. Gesundheitswesen. 2005 Aug;67 Suppl 1:S172-5.
  51. Teodorczuk A, Firbank MJ, Pantoni L, et al. Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. Psychol Med. 2010 Apr;40(4):603-10.
  52. Firbank MJ, Teodorczuk A, van der Flier WM, et al. Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study. Br J Psychiatry. 2012 Jul;201(1):40-5.
  53. Arsava EM, Bayrlee A, Vangel M, et al. Severity of leukoaraiosis determines clinical phenotype after brain infarction. Neurology. 2011 Jul 5;77(1):55-61.
  54. Inzitari D. Leukoaraiosis: an independent risk factor for stroke? Stroke. 2003 Aug;34(8):2067-71.
  55. Jeerakathil T, Wolf PA, Beiser A, et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke. 2004 Aug;35(8):1857-61.
  56. Fu JH, Lu CZ, Hong Z, Dong Q, Luo Y, Wong KS. Extent of white matter lesions is related to acute subcortical infarcts and predicts further stroke risk in patients with first ever ischaemic stroke. J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):793-6.
  57. Streifler JY, Eliasziw M, Benavente OR, et al. Prognostic importance of leukoaraiosis in patients with symptomatic internal carotid artery stenosis. Stroke. 2002 Jun;33(6):1651-5.
  58. Kuller LH, Longstreth WT, Jr., Arnold AM, Bernick C, Bryan RN, Beauchamp NJ, Jr. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. Stroke. 2004 Aug;35(8):1821-5.
  59. Naka H, Nomura E, Wakabayashi S, et al. Frequency of asymptomatic microbleeds on T2*-weighted MR images of patients with recurrent stroke: association with combination of stroke subtypes and leukoaraiosis. AJNR Am J Neuroradiol. 2004 May;25(5):714-9.
  60. Neumann-Haefelin T, Hoelig S, Berkefeld J, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke. 2006 Oct;37(10):2463-6.
  61. Verdelho A, Madureira S, Ferro JM, et al. Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. Stroke. 2012 Dec;43(12):3331-5.
  62. Boxer AL, Kramer JH, Johnston K, Goldman J, Finley R, Miller BL. Executive dysfunction in hyperhomocystinemia responds to homocysteine-lowering treatment. Neurology. 2005 Apr 26;64(8):1431-4.
  63. Fujita S, Kawaguchi T, Uehara T, Fukushima K. Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability. Int Psychogeriatr. 2005 Dec;17(4):689-98.
  64. Cicero AF, Borghi C. Evidence of clinically relevant efficacy for dietary supplements and nutraceuticals. Curr Hypertens Rep. 2013 Jun;15(3):260-7.
  65. Bagoly E, Feher G, Szapary L. The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies. Orv Hetil. 2007 Jul 22;148(29):1353-8.
  66. Diamond BJ, Bailey MR. Ginkgo biloba: indications, mechanisms, and safety. Psychiatr Clin North Am. 2013 Mar;36(1):73-83.
  67. Mashayekh A, Pham DL, Yousem DM, Dizon M, Barker PB, Lin DD. Effects of Ginkgo biloba on cerebral blood flow assessed by quantitative MR perfusion imaging: a pilot study. Neuroradiology. 2011 Mar;53(3):185-91.
  68. Patyar S, Prakash A, Modi M, Medhi B. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep. 2011;63(3):618-28.
  69. Valikovics A. Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz. 2007 Jul 30;60(7-8):301-10.
  70. Zhang SJ, Xue ZY. Effect of Western medicine therapy assisted by Ginkgo biloba tablet on vascular cognitive impairment of none dementia. Asian Pac J Trop Med. 2012 Aug;5(8):661-4.
  71. Wei J-j, Zhou Y-l. Treatment of posterior circulation ischemia with gastrodin and betahistine. Practical Clinical Medicine. 2012;13(4).
  72. Baek JH, Bernstein EE, Nierenberg AA. One-carbon metabolism and bipolar disorder. Aust N Z J Psychiatry. 2013 Nov;47(11):1013-8.
  73. Cacciapuoti F. Lowering homocysteine levels may prevent cardiovascular impairments? Possible therapeutic behaviors. Blood Coagul Fibrinolysis. 2012 Dec;23(8):677-9.
  74. Hankey GJ, Ford AH, Yi Q, et al. Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis. Stroke. 2013 Aug;44(8):2232-9.
  75. Ji Y, Tan S, Xu Y, et al. Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: A meta-analysis. Neurology. 2013 Oct 8;81(15):1298-307.
  76. Davinelli S, Sapere N, Visentin M, Zella D, Scapagnini G. Enhancement of mitochondrial biogenesis with polyphenols: combined effects of resveratrol and equol in human endothelial cells. Immun Ageing. 2013;10(1):28.
  77. de la Rosa AP, Montoya AB, Martinez-Cuevas P, et al. Tryptic amaranth glutelin digests induce endothelial nitric oxide production through inhibition of ACE: antihypertensive role of amaranth peptides. Nitric Oxide. 2010 Sep 15;23(2):106-11.
  78. Heinisch BB, Francesconi M, Mittermayer F, et al. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Eur J Clin Invest. 2010 Feb;40(2):148-54.
  79. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des. 2013;19(34):6064-93.
  80. Trombetta D, Cimino F, Cristani M, et al. In vitro protective effects of two extracts from bergamot peels on human endothelial cells exposed to tumor necrosis factor-alpha (TNF-alpha). J Agric Food Chem. 2010 Jul 28;58(14):8430-6.
  81. Voloshyna I, Hussaini SM, Reiss AB. Resveratrol in cholesterol metabolism and atherosclerosis. J Med Food. 2012 Sep;15(9):763-73.
  82. Wongpradabchai S, Chularojmontri L, Phornchirasilp S, Wattanapitayakul SK. Protective effect of Phyllanthus emblica fruit extract against hydrogen peroxide-induced endothelial cell death. J Med Assoc Thai. 2013 Jan;96 Suppl 1:S40-8.
  83. Cicero AF, Tartagni E, Ertek S. Nutraceuticals for metabolic syndrome management: From laboratory to benchside. Curr Vasc Pharmacol. 2013 Apr 25.
  84. Huang HY, Korivi M, Tsai CH, Yang JH, Tsai YC. Supplementation of Lactobacillus plantarum K68 and fruit-vegetable ferment along with high fat-fructose diet attenuates metabolic syndrome in rats with insulin resistance. Evid Based Complement Alternat Med. 2013;2013:943020.
  85. Jung MH, Seong PN, Kim MH, Myong NH, Chang MJ. Effect of green tea extract microencapsulation on hypertriglyceridemia and cardiovascular tissues in high fructose-fed rats. Nutr Res Pract. 2013 Oct;7(5):366-72.
  86. Kaur G, C M. Amelioration of obesity, glucose intolerance, and oxidative stress in high-fat diet and low-dose streptozotocin-induced diabetic rats by combination consisting of “curcumin with piperine and quercetin”. ISRN Pharmacol. 2012;2012:957283.
  87. Villalba JM, de Cabo R, Alcain FJ. A patent review of sirtuin activators: an update. Expert Opin Ther Pat. 2012 Apr;22(4):355-67.
  88. Arivazhagan P, Ramanathan K, Panneerselvam C. Effect of DL-alpha-lipoic acid on mitochondrial enzymes in aged rats. Chem Biol Interact. 2001 Nov 28;138(2):189-98.
  89. Bauerly K, Harris C, Chowanadisai W, et al. Altering pyrroloquinoline quinone nutritional status modulates mitochondrial, lipid, and energy metabolism in rats. PLoS One. 2011;6(7):e21779.
  90. Binukumar BK, Gupta N, Sunkaria A, et al. Protective efficacy of coenzyme Q10 against DDVP-induced cognitive impairments and neurodegeneration in rats. Neurotox Res. 2012 May;21(4):345-57.
  91. Chowanadisai W, Bauerly KA, Tchaparian E, Wong A, Cortopassi GA, Rucker RB. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. J Biol Chem. 2010 Jan 1;285(1):142-52.
  92. Gomez LA, Heath SH, Hagen TM. Acetyl-L-carnitine supplementation reverses the age-related decline in carnitine palmitoyltransferase 1 (CPT1) activity in interfibrillar mitochondria without changing the L-carnitine content in the rat heart. Mech Ageing Dev. 2012 Feb-Mar;133(2-3):99-106.
  93. Jun DW, Cho WK, Jun JH, et al. Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction. Liver Int. 2011 Oct;31(9):1315-24.
  94. Valdecantos MP, Perez-Matute P, Gonzalez-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martinez JA. Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function. J Nutr Biochem. 2012 Dec;23(12):1676-84.
  95. Phang M, Lincz LF, Garg ML. Eicosapentaenoic and docosahexaenoic acid supplementations reduce platelet aggregation and hemostatic markers differentially in men and women. J Nutr. 2013 Apr;143(4):457-63.
  96. Ramprasath VR, Jones PJ. Anti-atherogenic effects of resveratrol. Eur J Clin Nutr. 2010 Jul;64(7):660-8.
  97. Yang Y, Shi Z, Reheman A, et al. Plant food delphinidin-3-glucoside significantly inhibits platelet activation and thrombosis: novel protective roles against cardiovascular diseases. PLoS One. 2012;7(5):e37323.
  98. Lauver DA, Driscoll EM, Lucchesi BR. Disodium disuccinate astaxanthin prevents carotid artery rethrombosis and ex vivo platelet activation. Pharmacology. 2008;82(1):67-73.
  99. Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997;23(4):349-56.